Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO

Last updated: September 27, 2011
Sponsor: Warner Chilcott
Overall Status: Completed

Phase

3

Condition

Osteoporosis

Post-menopausal Osteopenia

Treatment

N/A

Clinical Study ID

NCT00577421
2002157
  • Ages > 55
  • Female

Study Summary

A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, RVE1998080, and RVE2001079 (NCT01249261)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • have satisfactorily completed Clinical Study RVE2001079 (Year 8 extension study)

Exclusion

Exclusion Criteria:

  • Can not use any bone modifying substances except risedronate

Study Design

Total Participants: 32
Study Start date:
June 01, 2003
Estimated Completion Date:
January 31, 2006

Study Description

A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, RVE1998080, and RVE2001079 (NCT01249261)

Connect with a study center

  • Research Site

    Concord,
    Australia

    Site Not Available

  • Research Facility

    Sienna,
    Italy

    Site Not Available

  • Research Facility

    Warsaw,
    Poland

    Site Not Available

  • Research Facility

    Barcelona,
    Spain

    Site Not Available

  • Research Facility

    Goteborg,
    Sweden

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.